

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-23. (canceled)

24. (currently amended) A method of manufacturing a tissue matrix comprising seeding human placental stem cells ~~from a mammalian placenta~~ into or onto a tissue matrix, wherein said stem cells are from a mammalian human placenta that has been treated to remove placental blood drained of cord blood and flushed to remove residual blood.

25. (previously presented) The method of claim 24, wherein said tissue matrix is an artificial tissue matrix.

26. (previously presented) The method of claim 24, wherein said tissue matrix is a tissue matrix produced from natural tissue.

27. (currently amended) The method of claim [[26]] 24, wherein said ~~natural~~ tissue matrix is a decellularized tissue.

28. (previously presented) The method of claim 27, wherein said tissue is an organ or part of an organ.

29. (currently amended) The method of claim 24, wherein said stem cells are SSEA3⁻, SSEA4⁻, or OCT-4⁺ and ABC-p⁺.

30. (previously presented) The method of claim 29, wherein said stem cells are CD10⁺, CD29⁺, CD34⁻, CD44⁺, CD45⁻, CD54⁺, CD90⁺, SH2⁺, SH3⁺, or SH4⁺, or any combination of the foregoing.

31. (previously presented) The method of claim 24, wherein said stem cells are CD34⁺.

32. (currently amended) The method of claim 24, wherein said stem cells are obtained from a placenta that has been perfused for at least 2 hours.

33. (currently amended) The method of claim 24, wherein said stem cells are obtained from a placenta that has been perfused for at least 12 hours.

34. (currently amended) The method of claim 24, wherein said stem cells are obtained from a placenta that has been perfused for at least 24 hours.

35. (previously presented) The method of claim 27, wherein said decellularized tissue is contacted with serum and fibronectin prior to said seeding.

36. (previously presented) The method of claim 35, wherein said decellularized tissue is additionally contacted with a glycosaminoglycan prior to said seeding.

37. (previously presented) The method of claim 36, wherein said glycosaminoglycan is heparin.

38. (previously presented) The method of claim 37, wherein said fibronectin and said heparin are present in a ratio of from about 0.1:1 to about 10:0.1 fibronectin:heparin.

39. (previously presented) The method of claim 24, wherein said stem cells are seeded by injection into said tissue.

40. (previously presented) The method of claim 24, wherein said stem cells are seeded through the tissue's vasculature.

41. (currently amended) A tissue matrix made according to the method of claim 25, wherein said human placental stem cells comprise CD34⁻ stem cells.

42. (currently amended) A tissue matrix made according to the method of claim 27, wherein said human placental stem cells comprise CD34⁻ stem cells.

43. (currently amended) A tissue matrix made according to the method of claim 38, wherein said human placental stem cells comprise CD34⁻ stem cells.

44. (new) A tissue matrix made according to the method of claim 24, wherein said human placental stem cells comprise CD34⁻ stem cells.

45. (new) A tissue matrix made according to the method of claim 26, wherein said human placental stem cells comprise CD34⁻ stem cells.

46. (new) A tissue matrix made according to the method of claim 41, wherein said human placental stem cells are CD34⁻.

47. (new) A tissue matrix made according to the method of claim 42, wherein said human placental stem cells are CD34⁻.

48. (new) A tissue matrix made according to the method of claim 43, wherein said human placental stem cells are CD34⁻.

49. (new) A tissue matrix made according to the method of claim 44, wherein said human placental stem cells are CD34⁻.

50. (new) A tissue matrix made according to the method of claim 45, wherein said human placental stem cells are CD34⁻.

INTERVIEW SUMMARY

An in-person interview was held on June 22, 2006 at the United States Patent and Trademark Office between Applicant's representatives Richard T. Girards, Jr., Nikolaos C. George, Lawrence S. Graham (collectively, "Applicant's attorneys"), and Examiner Qian Janice Li and Supervisory Patent Examiner David T. Nguyen (collectively, "the Examiners"). Applicant and Applicant's attorneys thank the Examiners for the courtesies extended during the Interview. In the Interview, Applicant's attorneys and the Examiners discussed all pending claims, and the pending bases of rejection. In particular, Applicant's attorneys and the Examiner discussed the nature of certain placental stem cells. Applicant's attorneys proposed amending the claims to recite "placental stem cell," and to provide evidence that placental stem cells are different from other types of stem cells. Applicant's attorneys proposed amending the claims to recite "human" in place of "mammalian." The present Amendment reflects the discussions in the Interview.